Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
about
Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.The role of clofarabine in acute myeloid leukemia.Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.Short-term therapeutic effects of low-dose cytarabine plus surgical resection on elderly patients with trigeminal nerve tumor and safety observation.Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML PatientsClofarabine in the treatment of acute myeloid leukemia in older adultsAzacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsStrategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemiaGenetic and epigenetic variants contributing to clofarabine cytotoxicity.Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemiaEpigenetic aspects of MDS and its molecular targeted therapy.Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Acute myeloid leukemia in the elderly: do we know who should be treated and how?Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Evolving treatment strategies in patients with high-risk acute myeloid leukemia.New treatments and strategies in acute myeloid leukemia.Clofarabine desensitization: A case report: Leukemia research reports.Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure.Clofarabine and Cytarabine Regimen for Acute Myeloid Leukemia.Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-M
P2860
Q33412609-100FB979-E819-474D-A307-6B295BC053F9Q33417145-2F37A5FE-DCCF-41AB-BF34-795A8E607137Q33702412-96A690A9-BAFF-41AF-B484-69BB4F631745Q33903024-DFBCC672-072D-4A4A-8F15-74A1CA3F9A57Q34298181-2B463B54-D40B-4E82-B1B2-DE393A49DBC4Q34631111-F8EDA673-AE77-4E42-A86D-AE7FB852EA53Q35277528-571FA9CF-8B64-4AE9-AB89-2D17D61C9CC2Q36152664-BC549E8A-512C-4B0D-BC08-28AB88FE5F4DQ36478979-1C428175-6D81-4F44-9CD3-3373E4503154Q36721055-D5426BEE-E7DA-41A3-9C99-88D1AA2230DDQ36776439-779FB67B-55F7-4B26-91FE-1926442AED99Q36804633-5022705B-328A-4831-8755-0CE90517DCD9Q37000485-5737CC6C-60C1-4A65-953C-EC95EB7A4218Q37153361-A1C12E52-3074-4986-99AC-D8B19965019EQ37153800-54DC5C90-6690-4C57-BB6A-AD393498DBD5Q37383528-AF147750-7C9E-411C-B548-BA7BEB25FC24Q37713068-5CB7B281-6770-46C8-BF07-6E83D8DC861FQ38051195-CFB804DB-EF53-4280-AD45-DA981549593BQ38103753-B6ACB26E-31F2-4712-AD0D-CE9AA35FF227Q38104287-35B575A9-CE29-4507-B015-5E577DF55622Q38124066-23C8892C-E4A4-4B89-B59E-CAAE47C16E84Q38161965-AB6E14C9-8CF8-4B41-966B-28137ABF6528Q38179026-B37FB063-3DC1-46ED-B670-BF1AB0402606Q41881090-EB264E0D-D4BA-421E-97D7-BF9CAE83C87EQ42268932-D1D6D3D6-94B9-4818-BDDC-95AED7377E34Q42414589-FAA3CD46-E939-4364-B671-1E1D986FB1D4Q42564240-3463CA58-7CFB-44CE-998E-F4B095169FFBQ42705834-35A7AE89-3269-4D67-8265-343F19993E09Q51098678-A6BFB637-7A4D-4E1F-83E3-DE5370204873
P2860
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 January 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clofarabine plus low-dose cyta ...... ne therapy for older patients.
@en
Clofarabine plus low-dose cyta ...... ne therapy for older patients.
@nl
type
label
Clofarabine plus low-dose cyta ...... ne therapy for older patients.
@en
Clofarabine plus low-dose cyta ...... ne therapy for older patients.
@nl
prefLabel
Clofarabine plus low-dose cyta ...... ne therapy for older patients.
@en
Clofarabine plus low-dose cyta ...... ne therapy for older patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
Clofarabine plus low-dose cyta ...... ne therapy for older patients.
@en
P2093
Jan Burger
Jennie Feliu
Xuelin Huang
Xuemei Wang
P2860
P304
P356
10.1002/CNCR.27429
P407
P50
P577
2012-01-26T00:00:00Z